Using advanced mammography techniques to assess breast cancer treatment response
Official title: Contrast Enhanced Digital Mammography for Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy
Run by Stony Brook University · NCT06220214 · Data updated 2026-11-12
This study is testing two new mammography techniques to see if they can better predict how well chemotherapy is working for people with locally advanced breast cancer.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 30 (estimated) |
| Sponsor | Stony Brook University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Stony Brook, New York) |
| Status | Recruiting |
| Started | March 6, 2024 |
| Main results expected | July 31, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT06220214 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with invasive locally advanced breast cancer who plan to receive at least 4 cycles of neoadjuvant chemotherapy.
✕Probably not a fit
Patients who are pregnant, have allergies to the contrast agent, decreased kidney function, or diabetes may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares two advanced mammography techniques, contrast-enhanced digital mammography (CEDM) and contrast-enhanced digital breast tomosynthesis (CEDBT), with breast MRI to evaluate their effectiveness in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. The Siemens MAMMOMAT device will be used to obtain both 2D and 3D images of the breast, allowing for improved detection and localization of cancer. Participants will undergo these imaging procedures over a period of up to 18 weeks as part of their treatment plan.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments of treatment response in breast cancer patients, potentially improving outcomes.
How similar studies have gone: Other studies have shown promise in using advanced imaging techniques for breast cancer assessment, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis with either type of invasive locally advanced breast cancer regardless of hormone receptor or Her2 status * Plan to receive at least 4 cycles of neoadjuvant chemotherapy ahead of definitive surgery Exclusion Criteria: * Pregnancy * Allergy/sensitivity to contrast agent * Decreased kidney function * Diabetes
Where it's running
-
Stony Brook Breast Center
Stony Brook, New York, United States Recruiting
Study contacts
- Principal investigator: Alison Stopeck, MD — Stony Brook Cancer Center
- Study coordinator: Alison Stopeck, MD
- Email: alison.stopeck@stonybrookmedicine.edu
- Phone: 631-444-7217
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-surgical treatment for breast cancer after chemotherapy
This study tests if using radiotherapy alone is a safe and effective option for breast cancer patients who have responded well to chemotherapy, instead of undergoing surgery.
-
Personalized treatment for breast cancer using new drug agents
This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.
-
Combining pembrolizumab with cryoablation for metastatic breast cancer
This study is testing if combining a drug called pembrolizumab with a freezing treatment can help people with advanced triple negative breast cancer feel better compared to just using the drug alone.
-
Precision neoadjuvant therapy for operable breast cancer
This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.
-
Understanding how tumor shrinkage predicts cancer response in early breast cancer patients
This study tests if measuring how much breast tumors shrink during chemotherapy can help predict how well the treatment will work for women with early-stage breast cancer.
-
Combining radiation therapy with pembrolizumab and olaparib for certain breast cancers
This study tests if adding pembrolizumab, with or without olaparib, to standard radiation therapy can help women with advanced breast cancer feel better compared to just radiation therapy alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.